Fully integrated french CDMO
Skyepharma is a key player in drug development and delivery of oral technologies serving the global pharmaceutical, biotech and consumer health industries.
Since 1996, we help our clients to offer the best drug for the benefit of the patient. In 2016, Skyepharma became the oral business Unit of the Vectura Group of Companies (www.vectura.com) and transformed into a fully integrated french CDMO [see our History].
- 1996 : Creation of Skyepharma
- 30 years of experience in oral solid dosage forms
- More than 110 employees including 1/4 in development department
- Located near Lyon, FRANCE
- Fully integrated CDMO since 2016
- Pharmaceutical Industry
- Food supplement Industry
- Develoment, Manufacturing and Packaging of classic & complex oral solid forms
- EU GMP certified facilities
- FDA approved since 1998. Last inspection in september 2019
- ANVISA approved since 2013
- Registered at Korean MFDS
- Products commercialized in US, EU, Brazil and Asia
- 40% of products exported to the US market
- March 2019 : 1st batch serialized and aggregated for US market
As a CDMO specialized in oral solid forms, our mission is to provide product development, manufacturing and packaging services to the healthcare industry through state-of-the-art facilities, scientific expertise and open, transparent relationships.
Our vision is Solving healthcare industry complexity.
Expert and agile french CDMO
Skyepharma is deeply committed to performance management and value creation for its clients. Our services are continuously improved to offer state-of-the-art global development, manufacturing and packaging services.
Our partners can rely on our agility and scientific expertise resulting in accelerated time to market and maximized value across all pharmaceutical lifecycle stages.
Our key differentiators
We use lean management practices such as visual management, 5S and 8D programmes.